{
    "organizations": [],
    "uuid": "5051731eda454367d5b30752cace7833b3a532c9",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-argenx-fy-total-operating-income-r/brief-argenx-fy-total-operating-income-rises-to-41-3-million-euros-idUSW8N1KI005",
    "ord_in_thread": 0,
    "title": "Argenx FY Total Operating Income Rises To 41.3 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 1 (Reuters) - Argenx Nv:\n* FY REVENUE EUR 36.4‍​ MILLION VERSUS EUR 14.7 MILLION YEAR AGO\n* FY TOTAL OPERATING INCOME EUR 41.3 MILLION VERSUS EUR 17.2 MILLION YEAR AGO\n* FY TOTAL COMPREHENSIVE LOSS EUR ‍​28.1 MILLION VERSUS LOSS OF EUR 21.4 MILLION YEAR AGO\n* CASH, CASH EQUIVALENTS AND CURRENT FINANCIAL ASSETS EUR 359.8 MILLION AT DEC. 31\n* IN 2018 PLANS TO REPORT FULL DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN GENERALIZED MG\n* FY OPERATING LOSS EUR 22.9 MILLION VERSUS LOSS EUR 21.4 MILLION YEAR AGO\n* IN 2018 PLANS TO REPORT TOPLINE DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN ITP\n* IN H2 PLANS TO REPORT INTERIM DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN PEMPHIGUS VULGARIS\n* BEFORE END-2018 PLANS TO PROGRESS ARGX-113 INTO PHASE 3 CLINICAL DEVELOPMENT IN GENERALIZED MG\n* IN Q2 PLANS TO REPORT FULL DATA OF PHASE 1 HEALTHY VOLUNTEER TRIAL WITH SUBCUTANEOUS FORMULATION OF ARGX-113\n* IN H2 PLANS TO PROVIDE AN UPDATE ON PHASE 1/2 CLINICAL TRIAL IN AML\n* BY END-YEAR PLANS TO REPORT FULL DATA OF AML PHASE 1/2 AND CTCL PHASE 2 CLINICAL TRIALS OF ARGX-110\n* BEFORE END-2018 PLANS TO LAUNCH PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-110 IN AML\n* BEFORE END-2018 PLANS TO REPORT FULL DATA OF PHASE 2 PROOF-OF-CONCEPT TRIAL FOR ARGX-113 IN ITP Source text: bit.ly/2t8eDce (Gdynia Newsroom)\n ",
    "published": "2018-03-01T14:41:00.000+02:00",
    "crawled": "2018-03-02T19:40:15.059+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "argenx",
        "nv",
        "fy",
        "revenue",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "total",
        "operating",
        "income",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "total",
        "comprehensive",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "cash",
        "cash",
        "equivalent",
        "current",
        "financial",
        "asset",
        "eur",
        "million",
        "plan",
        "report",
        "full",
        "data",
        "phase",
        "trial",
        "generalized",
        "mg",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "plan",
        "report",
        "topline",
        "data",
        "phase",
        "trial",
        "itp",
        "h2",
        "plan",
        "report",
        "interim",
        "data",
        "phase",
        "trial",
        "pemphigus",
        "vulgaris",
        "plan",
        "progress",
        "phase",
        "clinical",
        "development",
        "generalized",
        "mg",
        "q2",
        "plan",
        "report",
        "full",
        "data",
        "phase",
        "healthy",
        "volunteer",
        "trial",
        "subcutaneous",
        "formulation",
        "h2",
        "plan",
        "provide",
        "update",
        "phase",
        "clinical",
        "trial",
        "aml",
        "plan",
        "report",
        "full",
        "data",
        "aml",
        "phase",
        "ctcl",
        "phase",
        "clinical",
        "trial",
        "plan",
        "launch",
        "phase",
        "trial",
        "aml",
        "plan",
        "report",
        "full",
        "data",
        "phase",
        "trial",
        "itp",
        "source",
        "text",
        "gdynia",
        "newsroom"
    ]
}